{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["12"],"submitter":["Trejo-Solis C"],"pubmed_abstract":["<h4>Background</h4>Glioblastoma multiforme (GBM) is the most aggressive of the primary brain tumors, with a grim prognosis despite intensive treatment. In the past decades, progress in research has not significantly increased overall survival rate.<h4>Methods</h4>The in vitro antineoplastic effect and mechanism of action of Casiopeina III-ia (Cas III-ia), a copper compound, on rat malignant glioma C6 cells was investigated.<h4>Results</h4>Cas III-ia significantly inhibited cell proliferation, inducing autophagy and apoptosis, which correlated with the formation of autophagic vacuoles, overexpression of LC3, Beclin 1, Atg 7, Bax and Bid proteins. A decrease was detected in the mitochondrial membrane potential and in the activity of caspase 3 and 8, together with the generation of intracellular reactive oxygen species (ROS) and increased activity of c-jun NH(2)-terminal kinase (JNK). The presence of 3-methyladenine (as selective autophagy inhibitor) increased the antineoplastic effect of Cas III-ia, while Z-VAD-FMK only showed partial protection from the antineoplastic effect induced by Cas III-ia, and ROS antioxidants (N-acetylcysteine) decreased apoptosis, autophagy and JNK activity. Moreover, the JNK -specific inhibitor SP600125 prevented Cas III-ia-induced cell death.<h4>Conclusions</h4>Our data suggest that Cas III-ia induces cell death by autophagy and apoptosis, in part due to the activation of ROS -dependent JNK signaling. These findings support further studies of Cas III-ia as candidate for treatment of human malignant glioma."],"journal":["BMC cancer"],"pagination":["156"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC3404907"],"repository":["biostudies-literature"],"pubmed_title":["Copper compound induces autophagy and apoptosis of glioma cells by reactive oxygen species and JNK activation."],"pmcid":["PMC3404907"],"pubmed_authors":["Rodriguez-Enriquez S","Jimenez-Farfan D","Sotelo J","Fernandez-Valverde F","Trejo-Solis C","Cruz-Salgado A","Ruiz-Azuara L"],"additional_accession":[]},"is_claimable":false,"name":"Copper compound induces autophagy and apoptosis of glioma cells by reactive oxygen species and JNK activation.","description":"<h4>Background</h4>Glioblastoma multiforme (GBM) is the most aggressive of the primary brain tumors, with a grim prognosis despite intensive treatment. In the past decades, progress in research has not significantly increased overall survival rate.<h4>Methods</h4>The in vitro antineoplastic effect and mechanism of action of Casiopeina III-ia (Cas III-ia), a copper compound, on rat malignant glioma C6 cells was investigated.<h4>Results</h4>Cas III-ia significantly inhibited cell proliferation, inducing autophagy and apoptosis, which correlated with the formation of autophagic vacuoles, overexpression of LC3, Beclin 1, Atg 7, Bax and Bid proteins. A decrease was detected in the mitochondrial membrane potential and in the activity of caspase 3 and 8, together with the generation of intracellular reactive oxygen species (ROS) and increased activity of c-jun NH(2)-terminal kinase (JNK). The presence of 3-methyladenine (as selective autophagy inhibitor) increased the antineoplastic effect of Cas III-ia, while Z-VAD-FMK only showed partial protection from the antineoplastic effect induced by Cas III-ia, and ROS antioxidants (N-acetylcysteine) decreased apoptosis, autophagy and JNK activity. Moreover, the JNK -specific inhibitor SP600125 prevented Cas III-ia-induced cell death.<h4>Conclusions</h4>Our data suggest that Cas III-ia induces cell death by autophagy and apoptosis, in part due to the activation of ROS -dependent JNK signaling. These findings support further studies of Cas III-ia as candidate for treatment of human malignant glioma.","dates":{"release":"2012-01-01T00:00:00Z","publication":"2012 Apr","modification":"2025-04-21T16:34:13.417Z","creation":"2019-03-27T00:55:57Z"},"accession":"S-EPMC3404907","cross_references":{"pubmed":["22540380"],"doi":["10.1186/1471-2407-12-156"]}}